Nih covid-19 treatment guidelines strongly recommend use of regen-cov™ (casirivimab with imdevimab) in outpatients at high risk of clinical progression

Tarrytown, n.y., april 9, 2021 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) announced today that newly updated national institutes of health (nih) covid-19 treatment guidelines strongly recommend that regen-cov™ (casirivimab with imdevimab) be used in non-hospitalized covid-19 patients ("outpatients") at high risk of clinical progression.
REGN Ratings Summary
REGN Quant Ranking